Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease

Am J Hematol. 2005 Aug;79(4):337-9. doi: 10.1002/ajh.20418.

Abstract

Two human immunodeficiency virus-infected patients who needed etoposide therapy to control exacerbations of Castleman disease received four infusions of rituximab. Clinical and virologic relapses with increased blood human herpesvirus-8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / blood
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Castleman Disease / complications
  • Castleman Disease / drug therapy*
  • Castleman Disease / virology
  • DNA, Viral / blood
  • HIV Infections / complications*
  • HIV Infections / virology
  • Herpesvirus 8, Human / isolation & purification
  • Humans
  • Male
  • Middle Aged
  • Rituximab
  • Sarcoma, Kaposi / complications*
  • Sarcoma, Kaposi / virology
  • Treatment Failure

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • DNA, Viral
  • Rituximab